Hostname: page-component-54dcc4c588-gwv8j Total loading time: 0 Render date: 2025-09-26T04:15:15.481Z Has data issue: false hasContentIssue false

Psychosocial interventions for people with comorbid substance use disorders in people with severe mental health conditions in low- and middle-income countries: scoping review

Published online by Cambridge University Press:  22 September 2025

Awoke Mihretu*
Affiliation:
Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity Building, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Abebaw Fekadu
Affiliation:
Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity Building, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia Department of Global Health & Infection, Brighton and Sussex Medical School, Brighton, UK
Azeb Asaminew Alemu
Affiliation:
Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity Building, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
Charlotte Hanlon
Affiliation:
Department of Psychiatry, WHO Collaborating Centre for Mental Health Research and Capacity Building, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia Centre for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, Addis Ababa, Ethiopia Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK
*
Correspondence: Awoke Mihretu. Email: awoke.mihretu@aau.edu.et
Rights & Permissions [Opens in a new window]

Abstract

Background

The high comorbidity of substance use disorders (SUDs) among people with severe mental health conditions (MHCs) poses major challenges to providing effective care, particularly in low- and middle-income countries (LMICs), where treatment options are limited.

Aims

The aim of this scoping review was to produce an overview of the current evidence on psychosocial interventions for people with comorbid MHCs and SUDs in LMICs.

Method

The following databases were searched from their inception to 23 July 2024: PubMed/Medline, Global Health, Embase, PsycINFO and Global Index Medicus. We also searched for grey literature, using Google Scholar, ProQuest and Clinicaltrials.gov. Reporting was according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) Checklist. Studies were eligible if they focused on any psychosocial intervention targeting substance use in people with severe MHCs from LMICs. Of the 6304 records screened by titles and abstracts, 138 full-text articles were assessed and included for data extraction.

Results

Of the 6304 records screened by titles and abstracts, 138 full-text articles were assessed and 13 articles were included for data extraction. Many of the studies (n = 9) had a quasi-experimental design, and were from Latin America and South Asia. Four studies were randomised controlled trials. The primary outcomes examined were substance use abstinence, treatment engagement and retention, reduction in psychiatric symptoms, functioning and suicidal behaviours. Despite some heterogeneity in study designs, target populations and evaluated outcomes, interventions including various tobacco cessation programmes, screening and brief intervention with family support, and community-based programmes, have demonstrated positive outcomes in reducing tobacco, alcohol and khat use, respectively.

Conclusions

The review shows that there have been few initiatives to design and test psychosocial interventions for individuals with comorbid severe MHCs and SUDs in LMICs. There is a clear need to design and test feasible, acceptable, and effective interventions to address both severe MHCs and substance use when they co-occur.

Information

Type
Review
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Substance use disorder (SUD) – encompassing all forms of problematic substance use, including substance misuse, dependence, harmful use and hazardous use – is the most common and clinically significant comorbidity among individuals with severe mental health conditions (MHCs). Severe MHCs refer to major psychiatric disorders such as schizophrenia, bipolar disorder and major depressive disorder, particularly when these conditions are associated with prolonged disability. The term ‘dual diagnosis’ or ‘dual disorders’ is used to describe the co-occurrence of a severe MHC and an SUD. Reference Marel, Mills, Kingston, Gournay, Deady and Kay-Lambkin1,Reference Drake, Mueser, Brunette and McHugo2

In low- and middle-income countries (LMICs), mental and SUDs are among the leading contributors to the overall disease burden, accounting for an estimated 5.4% of the total burden. These conditions have substantial social and economic consequences. Reference Vigo, Jones, Atun and Thornicroft3,4 Mental illness and SUDs comprise an estimated 7.4% of global disability-adjusted life-years (DALYs) and 22.7% of global years lived with disability (YLDs). Reference Baingana, alAbsi, Becker and Pringle5 DALYs represent the total burden of disease and are calculated as the sum of years of life lost (YLLs) and YLDs. YLLs are estimated by multiplying the number of deaths by the standard life expectancy at the age of death. YLDs are calculated by multiplying the prevalence of a health condition by its assigned disability weight, adjusted for age, gender, location and year. Reference Vos, Lim, Abbafati, Abbas, Abbasi and Abbasifard6 The prevalence of SUDs among individuals with severe MHCs is markedly higher than in those without severe MHCs, posing significant challenges in clinical practice. Estimates from meta-analyses indicate that comorbid alcohol and/or other SUDs are observed in approximately 25% of individuals with major depressive disorder Reference Hunt, Malhi, Lai and Cleary7 and 42% of individuals with schizophrenia. Reference Hunt, Large, Cleary, Lai and Saunders8 Among people with bipolar disorder, the prevalence of alcohol use, cannabis use and illicit drug use has been estimated to be 42, 20 and 17%, respectively. Reference Hunt, Malhi, Cleary, Lai and Sitharthan9

In LMIC settings, the prevalence of co-occurring problematic SUDs and severe MHCs is reported to be high, ranging from 50 to 68%, primarily based on studies conducted in clinical populations. Reference Hauli, Ndetei, Jande and Kabangila10,Reference Weich and Pienaar11 In Ethiopia, where this review is situated, comorbid SUD is estimated to affect approximately a third of individuals with severe MHCs, with khat being the most commonly reported substance, followed by alcohol and tobacco. Reference Desalegn, Abdu and Hajure12Reference Tadesse and Mirkana15 The prevalence of any substance use among people with severe MHCs in Ethiopia has been reported to range from 25 to 40%, Reference Desalegn, Girma and Abdeta13Reference Ng, Medhin, Hanlon and Fekadu16 and the prevalence of alcohol use disorder specifically ranges between 10 and 25%. Reference Desalegn, Abdu and Hajure12,Reference Tadesse and Mirkana15

A minimal level of problematic substance use or any substance use among individuals with severe MHCs can have far-reaching negative effects, encompassing exacerbated psychiatric symptoms, recurrent hospital admissions, treatment non-adherence, compromised personal recovery, suicidal ideation or attempts, incarceration, homelessness, physical health complications, mortality Reference Ng, Medhin, Hanlon and Fekadu16Reference Najt, Fusar-Poli and Brambilla20 and physical health comorbidities. Reference Lee, McKibbin, Bourassa, Wykes and Andren21

To address common risk factors or mitigate the adverse impact of problematic substance use in individuals with severe MHCs, various psychosocial interventions have been tested, but many studies were from high-income countries (HICs). Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22 These interventions are rarely tested or adapted for LMICs. Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22

Recommendations and guidelines from HIC organisations such as the Substance Abuse and Mental Health Services Administration (SAMHSA), National Institute of Health (NIH) and American Psychological Association (APA) 23 have limited applicability to low-resource contexts. For example, assertive community treatment and token economy interventions, practiced in HICs, require significant human and material resources that may not be feasible in LMICs. There may also be limited peer support, insufficient availability of opioid antagonist treatments and a lack of robust frameworks for the early detection of problematic substance use among individuals with severe MHCs. Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22

As we anticipated that there would be very few primary studies on the topic in LMICs, and previous systematic reviews or meta-analyses have focused on single psychosocial interventions or specific substances, such as psychoactive drugs or alcohol, predominantly from HIC settings, we undertook a scoping review. We aimed to identify existing evidence on a broad range of psychosocial interventions for comorbid SUDs of all types in people with severe MHCs in LMICs, including any type of intervention study design and extending to include the grey literature.

Method

This scoping review protocol was registered at Open Science Framework (OSF): https://osf.io/867rf. We conducted and reported this scoping review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) Checklist. Reference Tricco, Lillie, Zarin, OBrien, Colquhoun and Levac24

Eligibility criteria

For this scoping review, articles, student theses and other grey literature were included. According to the PICOS framework for intervention studies (Population, Intervention, Control, Outcome and Setting), eligible studies included participants of all ages and psychosocial interventions targeting SUDs in people with severe MHCs. Psychosocial interventions encompassed psychological approaches aimed at enhancing motivation for behavioural change, medication adherence and treatment engagement, symptom reduction and relapse prevention. Psychosocial interventions also included interventions that focused on improving functioning and quality of life, and developing social skills, assertiveness and personal growth. Eligible studies also included any study relating to interventions for this group, including randomised controlled trials, controlled before-after, pre-post, pilot, naturalistic and other intervention evaluation studies of people with comorbidity, as well as qualitative and mixed-methods studies that described interventions, their implementation and experiences of the intervention. Studies were required to have any comparison condition, including treatment as usual, a comparison between two interventions, waiting list controls and comparing pre- and post-intervention outcomes; and be conducted in LMICs, as per the World Bank classification at the time the study was conducted or reported. The specific settings could include community settings, prisons, primary or specialised healthcare settings, residential settings, traditional or religious healing sites, or any other community setting. The review focused on substance use only when it qualified as a form of problematic use – such as dependence, harmful use, hazardous use or a diagnosed SUD. The assessment tools included were those specifically designed to identify problematic substance use. This criterion was also applied to tobacco use, with a particular focus on nicotine dependence. Severe MHCs encompassed all forms of psychotic disorders, mood disorders and depressive disorders, as diagnosed by trained mental health professionals.

Exclusion

We excluded non-research publications (e.g. commentaries, editorials). Review papers were examined for the primary studies they included, and these studies were evaluated against the eligibility criteria to determine inclusion or exclusion.

Information sources

We searched five databases: PubMed/Medline, Global Health, Embase, PsycINFO and Global Index Medicus. For grey literature, including Master’s or PhD theses, we searched ProQuest. We also searched Clinicaltrials.gov for protocols of intervention study and conducted a targeted search in Google Scholar. We searched from database inception to 29 December 2023, and updated the review on 23 July 2024. We conducted both backward and forward citation searches of all included studies.

Search criteria

Our search strategy consisted of key terms, free text and controlled vocabulary search terms such as Medical Subject Heading/MeSH terms for PubMed/Medline, PsycINFO terms and Emtree terms for Embase (see Supplementary File 1 available at https://doi.org/10.1192/bjo.2025.10840). The main concepts connected by the Boolean operator ‘AND’ were severe MHCs, SUDs, dual diagnosis, psychosocial interventions and LMICs.

Selection of sources of evidence

After searching the databases, the results were exported to Rayyan, a web-based tool, used on Windows (Rayyan Systems Inc., Doha, Qatar; https://www.rayyan.ai). Reference Ouzzani, Hammady, Fedorowicz and Elmagarmid25 Following de-duplication, two independent reviewers, A.M. and A.A.A., performed title and abstract screening. A.M. and A.A.A. also conducted full-text screening and extracted data from included articles. Conflicts were resolved by senior authors of the study.

Data charting process

The data extraction form included the following: study name or title; year of publication; country/countries; setting details; study design; population and participant details; type, dose, delivery agent, model and other characteristics of the psychosocial intervention (psychotherapy, system-based intervention, social intervention, family intervention, psychoeducation); type of substance use; type of MHCs; assessment time points; primary and secondary outcome measures; outcomes and impacts.

Collating, summarising and reporting the results

We summarised the data with descriptive counts and frequencies, and presented the key findings in a narrative format.

Results

After de-duplication, 6304 records were identified and title/abstract screening undertaken. Of these, 138 full-text articles were assessed for eligibility, and 13 articles met the inclusion criteria for the review (Fig. 1). The majority (76%) of the assessed studies were not intervention studies. The remaining articles were excluded because they had the wrong population (i.e. did not address comorbid SUD and severe MHCs) or were conducted in settings outside LMICs.

Fig. 1 PRISMA flow diagram of the study selection process.

Overall characteristics of the studies

The studies were conducted across diverse settings, but from a small number of LMICs (Table 1): four studies from Brazil, two each from Iran and Thailand, and one study each from Ethiopia, Kenya, Somalia, India and Mexico. The settings included various centres specialising in psychosocial intervention for alcohol and other drug rehabilitation in Brazil, Reference Lima, Carvalho, Guimarães-Pereira, Loreto, Frallonardo and Ismael26 community-based residential care facilities in Mexico, Reference Marín-Navarrete, Torrens, Toledo-Fernández, Mestre-Pinto, Sánchez-Domínguez and Pérez-Lopez27 therapeutic community centres in Iran, Reference Zemestani and Ottaviani28 hospital discharges in the community in Somalia, Reference Odenwald, Lingenfelder, Peschel, Haibe, Warsame and Omer29 drop-in centres in Iran, Reference Alavi, Irani, Fattahi and Pakseresht30 psychiatric out-patient units within tertiary care hospitals in India, Reference Sinha, Kohli, Ghosh and Basu31 primary healthcare-based patients in the community in Ethiopia Reference Asher, Birhane, Weiss, Medhin, Selamu and Patel32 and psychiatric in-patients in Thailand. Reference Thapinta, Skulphan and Kittrattanapaiboon33 Moreover, the study engaged special populations, including Somali refugees in Kenya. Reference Widmann, Apondi, Musau, Warsame, Isse and Mutiso34 Participants across the studies were individuals with psychosis, psychotic depression and comorbid SUDs. The MHCs examined in the included studies were schizophrenia alone (n = 1), severe psychiatric or MHCs (n = 4), psychosis (n = 4), depressive disorders (n = 3) and mood disorders (n = 1).The substances examined in the studies included tobacco (n = 5), opioids (n = 1), alcohol alone and alcohol with other drugs (n = 3), SUDs (n = 2) and khat (n = 2).

Table 1 Characteristics and results of the included studies

BPRS, Brief Psychiatric Rating Scale; CBT, cognitive–behavioural therapy; RCT, randomised clinical trials; ASSIST, Alcohol, Smoking and Substance Involvement Screening Test; SUD, substance use disorder; MBRP, mindfulness-based relapse prevention; SCID-I, Structured Clinical Interview for DSM-IV Axis I Disorders; PHQ-9, Patient Health Questionnaire-9; PDS, Post-traumatic Diagnostic Scale; CIDI, Composite International Diagnostic Interview; MHC, mental health conditions; MINI, Mini-International Neuropsychiatric Interview; MoCA, Montreal Cognitive Assessment; GHQ-28, General Health Questionnaire-28; AUDIT, Alcohol Use Disorders Identification Test.

Only four of the 13 studies were randomised controlled trials. Participant numbers in the studies ranged from 35 to 498, with six studies having a sample size below 100. Eight studies were conducted in community settings, two took place in general hospitals and one in a specialised hospital. In eight studies, the intervention was delivered by mental health professionals, including psychiatrists, psychologists or psychiatric nurses. Intervention providers without formal degrees participated in three studies, particularly those focused on psychosocial rehabilitation.

Primary outcomes of the studies

The primary outcomes of the studies included substance use abstinence, treatment engagement and retention, psychiatric symptoms, functioning and suicidal behaviour. Specifically, these outcomes encompassed smoking cessation or tobacco abstinence and treatment retention, Reference Lima, Carvalho, Guimarães-Pereira, Loreto, Frallonardo and Ismael26,Reference Castaldelli-Maia, Loreto, Carvalho, Frallonardo and de Andrade36 reduction in psychotic symptoms measured by the Brief Psychiatric Rating Scale (BPRS), improvement in functioning and a decrease in hours spent chewing khat. Reference Zemestani and Ottaviani28 Additional outcomes assessed were depressive symptoms, evaluated with the Beck Depression Inventory-II (BDI-II) or the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Reference Zemestani and Ottaviani28 and khat use quantified by the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). Reference Asher, Birhane, Weiss, Medhin, Selamu and Patel32

Interventions

The studies focused on implementation of dual diagnosis screening (n = 1), tobacco cessation programmes (n = 4), psychological interventions (n = 3) and psychosocial rehabilitation (n = 3). None of the studies employed a rigorous cultural adaptation process. One study found that a dual diagnosis screening tool, delivered through a mobile phone application, was easy to apply, acceptable and had demonstrated sensitivity and specificity scores above 85%. Reference Marín-Navarrete, Torrens, Toledo-Fernández, Mestre-Pinto, Sánchez-Domínguez and Pérez-Lopez27 There were four studies focusing on tobacco cessation among people with severe MHCs. Reference Lima, Carvalho, Guimarães-Pereira, Loreto, Frallonardo and Ismael26,Reference Castaldelli-Maia, Carvalho, Armentano, Frallonardo, Alves and Andrade35,Reference Castaldelli-Maia, Loreto, Carvalho, Frallonardo and de Andrade36,Reference Castaldelli-Maia, da Silva, Campos, Moura, Zabert and Champagne38 The success rate for tobacco abstinence ranged from 29.1 to 44.4%. In one study, the attendance rate for tobacco cessation programmes was 42%. Factors associated with successful completion of these programmes included pre-intervention time to first cigarette of 5 min or more after waking and the use of nicotine patches as part of nicotine replacement therapy. Reference Castaldelli-Maia, Loreto, Carvalho, Frallonardo and de Andrade36 However, there was also resistance in integrating tobacco dependence treatment within primary care networks, particularly regarding the adoption of cognitive–behavioural therapy (CBT) and medication use in addiction treatment. Reference Castaldelli-Maia, da Silva, Campos, Moura, Zabert and Champagne38 In studies investigating tobacco interventions for individuals with severe MHCs, findings emphasised the importance of tailoring treatment methods based on the specific combination of comorbidities and the individual’s motivation stage. Additionally, the role of psychosocial techniques in increasing motivation and resolving environmental and situational challenges was highlighted. Effective psychiatric support to manage psychotic symptoms, mania and depression (with or without suicide risk) could also contribute to better engagement in substance use interventions. Reference Zaleski, Laranjeira, Marques, Ratto, Romano and Alves39

Psychological interventions, such as CBT, group therapy, screening and brief intervention, brief intervention with family support and mindfulness-based relapse prevention (MBRP), have been utilised. Both screening and brief intervention and MBRP have been shown to enhance motivation and reduce alcohol risk scores. There was no statistically significant difference in psychosis symptoms post-intervention in the MBRP group (P = 0.077). Reference Alavi, Irani, Fattahi and Pakseresht30 However, participants receiving MBRP reported significantly greater improvements in depression and cravings compared with those on treatment as usual. Reference Zemestani and Ottaviani28 Six-session (40–60 min per session) CBT was also promising in benefitting patients with alcohol dependence and severe depression. Reference Thapinta, Skulphan and Kittrattanapaiboon33 Screening and brief intervention with family support was also super-efficacious versus screening and brief intervention alone, in relation to functioning among individuals with schizophrenia and problematic substance use. Reference Thapinta, Skulphan and Kittrattanapaiboon33 An Indian study highlighted the potential of screening and brief interventions to reduce the frequency of heavy drinking and alcohol risk scores. Reference Sinha, Kohli, Ghosh and Basu31

Home-based and community-based rehabilitation programmes, lasting 5–6 weeks, included psychoeducation, monthly visits, counselling and stress management. The findings were positive for reducing khat use; however, there was no evidence of effectiveness in reducing problematic alcohol use. Reference Asher, Birhane, Weiss, Medhin, Selamu and Patel32,Reference Widmann, Apondi, Musau, Warsame, Isse and Mutiso34 A randomised controlled trial found no evidence of the effectiveness of community-based rehabilitation on alcohol use disorder (adjusted odds ratio 0.82, 95% CI 0.24–2.74; P = 0.74) at 12 months. Reference Asher, Birhane, Weiss, Medhin, Selamu and Patel32 Another study on a 6-week intensive home-based treatment programme demonstrated a reduction in khat use among out-patients. Reference Odenwald, Lingenfelder, Peschel, Haibe, Warsame and Omer29

Discussion

This scoping review aimed to provide an overview of current evidence on psychosocial interventions for individuals with severe MHCs and substance use in LMICs. We identified a limited number of primary studies focusing on intervention adaptation or testing in this population, with only four out of 13 studies being randomised controlled trials. These studies spanned eight LMICs, and their primary outcomes were varied, including substance use abstinence, treatment engagement and retention, reduction in psychiatric symptoms, functioning and suicidal behaviours.

The studies targeted a variety of substances, including tobacco, opioids, alcohol, khat and other drugs, using interventions such as early screening for dual conditions, tobacco cessation programmes, psychological interventions and psychosocial rehabilitation. However, there was no sufficient evidence on implementation processes, barriers or facilitators.

Some psychosocial interventions appear to be feasible and acceptable in LMICs among people with severe MHCs and SUDs. Reference Asher, Hanlon, Birhane, Habtamu, Eaton and Weiss40 Tobacco cessation programmes, screening and brief intervention with family support, and home-based programmes have demonstrated positive outcomes in reducing the use of tobacco, alcohol and khat, respectively. Reference Sinha, Kohli, Ghosh and Basu31,Reference Widmann, Apondi, Musau, Warsame, Isse and Mutiso34,Reference Castaldelli-Maia, da Silva, Campos, Moura, Zabert and Champagne38 However, the heterogeneity in outcomes, study designs and target populations made it difficult to draw concrete conclusions regarding the optimal type, mode, dosage and characteristics of psychosocial interventions for individuals with severe MHCs and co-occurring SUDs.

The feasibility and acceptability of the promising tobacco cessation programmes were largely limited to psychosocial care units. Various forms of CBT, such as brief CBT and mindfulness-based CBT, also demonstrated feasibility and acceptability in reducing depressive symptoms, addressing alcohol dependence and preventing substance relapse in settings like Iran and Thailand. Despite these successes, such interventions often required significant resources, including more trained healthcare providers, limiting their applicability in very low-resource settings. Reference Zemestani and Ottaviani28,Reference Thapinta, Skulphan and Kittrattanapaiboon33

The existing evidence was mostly limited to tobacco and alcohol. However, psychostimulants like khat, which were more prevalent in some low-resource contexts such as East Africa, pose additional challenges for individuals with severe MHCs. Reference Odenwald, Lingenfelder, Peschel, Haibe, Warsame and Omer29 Odenwald et al highlighted that although community-based interventions for psychosis were both feasible and acceptable in Somalia, challenges such as limited local capacity and comorbid khat use persisted. Therefore, adapting suitable interventions for people with severe MHCs and comorbid SUDs to low-resource settings remains critical.

There is an urgent need to promote guidelines for the screening and treatment of people with severe MHC and SUDs to achieve better outcomes, as concurrent disorders are often underdiagnosed, undertreated and more complex to manage. Reference Hakobyan, Vazirian, Lee-Cheong, Krausz, Honer and Schutz41 However, the current review found only one guideline from the Brazilian Association of Studies on Alcohol and Other Drugs (ABEAD) for the diagnosis and treatment of psychiatric comorbidity with alcohol and other substance dependence, which clearly described the scope and purpose of the guideline. Reference Zaleski, Laranjeira, Marques, Ratto, Romano and Alves39 Additionally, there was a study on the adaptation of an app to screen for dual disorders, which shows promise as a useful screening tool in residential addiction treatment centres.37 Previous global reviews identified 23 other guidelines, all of which were from HICs. Reference Hakobyan, Vazirian, Lee-Cheong, Krausz, Honer and Schutz41 The World Health Organization’s mental health Gap Action Programme Intervention Guide (mhGAP-IG 3.0) does not include specific interventions for the prevention and management of comorbidity between SUDs and severe MHCs. However, it recognises the detection of tobacco, alcohol and substance use among people visiting health facilities, and has potential for adaptation for people with severe MHCs. 42 Universal screening for substance use in individuals with severe MHCs appears ethically and scientifically justified. However, it should be preceded by the development and evaluation of effective interventions. Therefore, addressing both severe MHCs and SUDs concurrently should be a priority.

This review also underscores inequities in healthcare provision for individuals with severe MHCs and SUDs. Reference Druss and von Esenwein43 For individuals with severe MHCs and SUDs, even minimal substance use can have far-reaching consequences. Reference Hunt, Malhi, Cleary, Lai and Sitharthan17Reference Najt, Fusar-Poli and Brambilla20,Reference Smartt, Ketema, Frissa, Tekola, Birhane and Eshetu44 Although not considered in this review, comorbidities like HIV/AIDS, hypertension, diabetes and cardiovascular diseases are often prevalent in this population, Reference Lee, McKibbin, Bourassa, Wykes and Andren21 which underlines the need for a person-centred approach. Poor health outcomes in these populations can be attributed to barriers such as limited access to quality healthcare and routine screening, stigma from healthcare providers and a lack of knowledge about comorbid conditions. In some cases, substance use or physical health issues are overlooked or misinterpreted in individuals with severe MHCs, further complicating their treatment. Reference Mitchell, Malone and Doebbeling45,Reference Van Boekel, Brouwers, Van Weeghel and Garretsen46

The current study identified group therapy, CBT, brief interventions and MBRP as feasible psychosocial interventions in LMICs, in addition to psychosocial rehabilitation. In contrast, HICs have developed and tested a broader range of well-adapted psychosocial interventions for individuals with severe MHCs and SUDs. Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22 However, a Cochrane review indicated no clear superiority in efficacy among various psychosocial interventions – including CBT, motivational interviewing, case management, skills training and contingency management – either relative to each other or compared with treatment as usual. Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22 Although many psychotherapeutic approaches incorporate elements of motivational interviewing, Reference Miller and Rollnick47 evidence does not support its superior efficacy over other methods. Reference Hunt, Siegfried, Morley, Brooke-Sumner and Cleary22 Some interventions, such as assertive community treatment and token economy approaches, require substantial resources and may not be practical in LMICs settings. In contrast, low-resource interventions, such as motivational interviewing, psychoeducation and peer support, appear more promising. Additionally, many randomised controlled trials targeting severe MHCs exclude individuals with co-occurring substance use, thereby limiting the generalisability of their findings to dual diagnosis. Reference Mihretu, Nhunzvi, Fekadu, Norton and Teferra48

We also found that cultural use of certain substances, such as khat, which is not widely recognised as an SUD, may be overlooked in studies of dual diagnosis. Reference Mihretu, Nhunzvi, Fekadu, Norton and Teferra48 Khat is a stimulant with amphetamine-like properties, Reference Feyissa and Kelly49 commonly used in East Africa and among diaspora communities in Europe. Reference Ongeri, Kirui, Muniu, Manduku, Kirumbi and Atwoli50,Reference Bhui and Warfa51 Its use has been significantly associated with elevated rates of psychotic symptoms. At least one psychotic symptom was reported by 16.8% of khat users. Reference Ongeri, Kirui, Muniu, Manduku, Kirumbi and Atwoli50,Reference Babor52 Psychosis has been particularly linked to heavy or prolonged khat use and may also exacerbate pre-existing MHCs. Reference Babor52Reference Warfa, Bhui, Craig, Curtis, Mohamud and Stansfeld54 Khat use disorder has also been recognised as a valid diagnostic entity. Reference Duresso, Matthews, Ferguson and Bruno55 Khat use disorder meets the core diagnostic criteria for stimulant use disorder as outlined in the DSM-5. These include impaired control over use, significant social and occupational harm, and characteristic withdrawal symptoms such as depressed mood, irritability, fatigue, lack of motivation, hypersomnia and increased appetite. Reference Mihretu, Nhunzvi, Fekadu, Norton and Teferra48,Reference Mihretu, Fekadu, Norton, Habtamu and Teferra56

The methodological quality of the studies included in this review was a concern. Many studies employed non-randomised, uncontrolled experimental designs, which come with high risk of bias. Reference Andrade57 Some of the randomised controlled trials were underpowered to detect changes in the outcomes. Reference Asher, Hanlon, Birhane, Habtamu, Eaton and Weiss40 Although better-powered studies may reveal significant differences, it might still be important to consider the clinical significance of the existing findings as they stand. This further highlights the need for more rigorous research on dual diagnosis in LMICs. In contexts like Ethiopia, where this review was conducted, designing and implementing psychosocial interventions presents challenges, including limited human and material resources. However, contextual adaptation of these interventions remains feasible.58

Limitations of the scoping review

Because of the diversity of study designs, we were unable to conduct systematic risk-of-bias appraisal of the included studies. The wide variation in reported outcomes may have posed challenges in drawing strong conclusions across the evidence base.

In summary, our review has shown the limited efforts to design and test psychosocial interventions for individuals with severe MHCs and SUDs in LMICs. Unlike HICs, where evidence-based interventions exist, LMICs have not yet developed or tested effective solutions for this population. We strongly advocate for the design and testing of feasible, acceptable and effective interventions, such as dual screening programmes and integrated psychosocial interventions, to address both severe MHCs and substance use when they co-occur.

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1192/bjo.2025.10840

Data availability

All of the relevant data are included in this manuscript.

Author contributions

A.M. and A.A.A. did the searching and screening. A.M. drafted the protocol, with contributions from A.F. and C.H. All authors made critical intellectual contributions, read and approved the final manuscript and agreed to submission for publication.

Funding

This work was supported through the African Mental Health Research Initiative (AMARI) II, a programme of the DELTAS Africa Initiative. The DELTAS Africa Initiative is a programme of the Science for Africa Foundation being implemented with support from Wellcome Trust and the UK Foreign Commonwealth and Development Office. A.M. received support from the Wellcome Trust through grant number 222154/Z20/Z (SCOPE). C.H. receives support through a National Institute for Health and Care Research global health research group on homelessness and mental health in Africa (HOPE; grant number NIHR134325). The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health and Care Research or the Department of Health and Social Care, England. C.H. is also funded by the Wellcome Trust through grant numbers 222154/Z20/Z (SCOPE) and 223615/Z/21/Z (PROMISE).

Declaration of interest

None.

Ethical standards

Ethical approval was not required for this study. Review registration number: Open Science Framework identifier https://osf.io/867rf.

References

Marel, C, Mills, KL, Kingston, R, Gournay, K, Deady, M, Kay-Lambkin, F, et al. Guidelines on the Management of Co-Occurring Alcohol and Other Drug and Mental Health Conditions in Alcohol and Other Drug Treatment Settings 2nd ed. NHMRC Centre of Research Excellence in Mental Health and Substance Use, National Drug and Alcohol Research Centre, 2016.Google Scholar
Drake, RE, Mueser, KT, Brunette, MF, McHugo, GJ. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr Rehabil J 2004; 27: 360.10.2975/27.2004.360.374CrossRefGoogle ScholarPubMed
Vigo, D, Jones, L, Atun, R, Thornicroft, G. The true global disease burden of mental illness: still elusive. Lancet Psychiatry 2022; 9: 98100.10.1016/S2215-0366(22)00002-5CrossRefGoogle ScholarPubMed
WHO. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 2022; 9: 137–50.10.1016/S2215-0366(21)00395-3CrossRefGoogle Scholar
Baingana, F, alAbsi, M, Becker, AE, Pringle, B. Global research challenges and opportunities for mental health and substance-use disorders. Nature 2015; 527: S172–7.10.1038/nature16032CrossRefGoogle ScholarPubMed
Vos, T, Lim, SS, Abbafati, C, Abbas, KM, Abbasi, M, Abbasifard, M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396: 1204–22.10.1016/S0140-6736(20)30925-9CrossRefGoogle Scholar
Hunt, GE, Malhi, GS, Lai, HMX, Cleary, M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990–2019: systematic review and meta-analysis. J Affect Disord 2020; 266: 288304.CrossRefGoogle ScholarPubMed
Hunt, GE, Large, MM, Cleary, M, Lai, HMX, Saunders, JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depen 2018; 191: 234–58.10.1016/j.drugalcdep.2018.07.011CrossRefGoogle ScholarPubMed
Hunt, GE, Malhi, GS, Cleary, M, Lai, HMX, Sitharthan, T. Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: systematic review and meta-analysis. J Affect Disord 2016; 206: 331–49.10.1016/j.jad.2016.07.011CrossRefGoogle ScholarPubMed
Hauli, KA, Ndetei, DM, Jande, MB, Kabangila, R. The prevalence of substance use among psychiatric patients: the case study of Bugando Medical centre, Mwanza (northern Tanzania). Subst Abuse 2011; 32: 238–41.10.1080/08897077.2011.599253CrossRefGoogle Scholar
Weich, L, Pienaar, W. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. Afr J Psychiatry 2009; 12: 213–7.10.4314/ajpsy.v12i3.48496CrossRefGoogle ScholarPubMed
Desalegn, D, Abdu, Z, Hajure, M. Prevalence of tobacco dependence and associated factors among patients with schizophrenia attending their treatments at southwest Ethiopia; hospital-based cross-sectional study. PLoS One 2021; 16: e0261154.CrossRefGoogle ScholarPubMed
Desalegn, D, Girma, S, Abdeta, T. Quality of life and its association with current substance use, medication non-adherence and clinical factors of people with schizophrenia in southwest Ethiopia: a hospital-based cross-sectional study. Health Qual Life Outcomes 2020; 18: 82.10.1186/s12955-020-01340-0CrossRefGoogle ScholarPubMed
Molla, Z, Dube, L, Krahl, W, Soboka, M. Tobacco dependence among people with mental illness: a facility-based cross sectional study from southwest Ethiopia. BMC Res Notes 2017; 10: 289.10.1186/s13104-017-2608-7CrossRefGoogle ScholarPubMed
Tadesse, H, Mirkana, Y. Alcohol use disorder and its determinant factors among patients with schizophrenia attending treatment at mental specialized hospital, Addis Ababa, Ethiopia: a cross-sectional study. SAGE Open Med 2021; 9: 20503121211048748.CrossRefGoogle Scholar
Ng, LC, Medhin, G, Hanlon, C, Fekadu, A. Trauma exposure, depression, suicidal ideation, and alcohol use in people with severe mental disorder in Ethiopia. Soc Psychiatry Psychiatr Epidemiol 2019; 54: 835–42.10.1007/s00127-019-01673-2CrossRefGoogle ScholarPubMed
Hunt, GE, Malhi, GS, Cleary, M, Lai, HMX, Sitharthan, T. Comorbidity of bipolar and substance use disorders in national surveys of general populations, 1990-2015: systematic review and meta-analysis. J Affect Disord 2016; 206: 321–30.10.1016/j.jad.2016.06.051CrossRefGoogle ScholarPubMed
Dickey, B, Azeni, H, Weiss, R, Sederer, L. Schizophrenia, substance use disorders and medical co-morbidity. J Ment Health Policy Econ 2000; 3: 27–33.10.1002/1099-176X(200003)3:1<27::AID-MHP67>3.0.CO;2-P3.0.CO;2-P>CrossRefGoogle ScholarPubMed
Ziedonis, DM, Smelson, D, Rosenthal, RN, Batki, SL, Green, AI, Henry, RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005; 11: 315–39.10.1097/00131746-200509000-00005CrossRefGoogle ScholarPubMed
Najt, P, Fusar-Poli, P, Brambilla, P. Co-occurring mental and substance abuse disorders: a review on the potential predictors and clinical outcomes. Psychiat Res 2011; 186: 159–64.10.1016/j.psychres.2010.07.042CrossRefGoogle ScholarPubMed
Lee, AA, McKibbin, CL, Bourassa, KA, Wykes, TL, Andren, KAK. Depression, diabetic complications and disability among persons with comorbid schizophrenia and type 2 diabetes. Psychosomatics 2014; 55: 343–51.10.1016/j.psym.2013.12.015CrossRefGoogle ScholarPubMed
Hunt, GE, Siegfried, N, Morley, K, Brooke-Sumner, C, Cleary, M. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Db Syst Rev 2019; 2019: CD001088.Google Scholar
Center for Mental Health Services, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services. Integrated Treatment for Co-Occurring Disorders: Building Your Program. U.S. Department of Health and Human Services, 2019 (https://library.samhsa.gov/sites/default/files/ebp-kit-building-your-program-10112019.pdf).Google Scholar
Tricco, AC, Lillie, E, Zarin, W, OBrien, KK, Colquhoun, H, Levac, D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169: 467–73.10.7326/M18-0850CrossRefGoogle ScholarPubMed
Ouzzani, M, Hammady, H, Fedorowicz, Z, Elmagarmid, A. Rayyan—a web and mobile app for systematic reviews. Syst Rev 2016; 5: 110.10.1186/s13643-016-0384-4CrossRefGoogle ScholarPubMed
Lima, DR, Carvalho, CFC, Guimarães-Pereira, BBS, Loreto, AR, Frallonardo, FP, Ismael, F, et al. Abstinence and retention outcomes in a smoking cessation program among individuals with co-morbid substance use and mental disorders. J Psychiat Res 2020; 125: 121–8.10.1016/j.jpsychires.2020.03.014CrossRefGoogle Scholar
Marín-Navarrete, R, Torrens, M, Toledo-Fernández, A, Mestre-Pinto, JI, Sánchez-Domínguez, R, Pérez-Lopez, A, et al. Developing an app to screen for dual disorders: a tool for improving treatment services in Mexico. Front Psychiatry 2021; 12: 697598.10.3389/fpsyt.2021.697598CrossRefGoogle ScholarPubMed
Zemestani, M, Ottaviani, C. Effectiveness of mindfulness-based relapse prevention for co-occurring substance use and depression disorders. Mindfulness 2016; 7: 1347–55.10.1007/s12671-016-0576-yCrossRefGoogle Scholar
Odenwald, M, Lingenfelder, B, Peschel, W, Haibe, FA, Warsame, AM, Omer, A, et al. A pilot study on community-based outpatient treatment for patients with chronic psychotic disorders in Somalia: change in symptoms, functioning and co-morbid khat use. Int J Ment Health Syst 2012; 6: 118.10.1186/1752-4458-6-8CrossRefGoogle ScholarPubMed
Alavi, SMA, Irani, RD, Fattahi, P, Pakseresht, S. Effects of brief cognitive behavioral therapy on mental health in substance-related disorder: a randomized controlled trial. BMC Psychiatry 2023; 23: 924.10.1186/s12888-023-05413-4CrossRefGoogle ScholarPubMed
Sinha, A, Kohli, A, Ghosh, A, Basu, D. Efficacy of screening and brief intervention for hazardous alcohol use in patients with mood disorders: a randomized clinical trial from a psychiatric out-patient clinic in India. Asian J Psychiatry 2022; 73: 103138.10.1016/j.ajp.2022.103138CrossRefGoogle ScholarPubMed
Asher, L, Birhane, R, Weiss, HA, Medhin, G, Selamu, M, Patel, V, et al. Community-based rehabilitation intervention for people with schizophrenia in Ethiopia (RISE) cluster-randomised controlled trial: an exploratory analysis of impact on food insecurity, underweight, alcohol use disorder and depressive symptoms. Glob Ment Health (Camb) 2023; 10: e70.10.1017/gmh.2023.67CrossRefGoogle ScholarPubMed
Thapinta, D, Skulphan, S, Kittrattanapaiboon, P. Brief cognitive behavioral therapy for depression among patients with alcohol dependence in Thailand. Issues Ment Health Nurs 2014; 35: 689–93.10.3109/01612840.2014.917751CrossRefGoogle ScholarPubMed
Widmann, M, Apondi, B, Musau, A, Warsame, AH, Isse, M, Mutiso, V, et al. Comorbid psychopathology and everyday functioning in a brief intervention study to reduce khat use among Somalis living in Kenya: description of baseline multimorbidity, its effects of intervention and its moderation effects on substance use. Soc Psychiatry Psychiatr Epidemiol 2017; 52: 1425–34.10.1007/s00127-017-1368-yCrossRefGoogle Scholar
Castaldelli-Maia, JM, Carvalho, CFC, Armentano, F, Frallonardo, FP, Alves, TCTF, Andrade, AG, et al. Outcome predictors of smoking cessation treatment provided by an addiction care unit between 2007 and 2010. Rev Bras Psiquiatr 2013; 35: 338–46.10.1590/1516-4446-2012-0907CrossRefGoogle Scholar
Castaldelli-Maia, JM, Loreto, AR, Carvalho, CFC, Frallonardo, FP, de Andrade, AG. Retention predictors of a smoking treatment provided by a public psychosocial unit in Brazil. Int Rev Psychiatry 2014; 26: 515–23.10.3109/09540261.2014.928272CrossRefGoogle ScholarPubMed
Tantirangsee, N, Assanangkornchai, S. Prevalence, patterns, associated factors and severity of substance use among psychotic patients in southern Thailand. Asian J Psychiatr 2015; 13: 30–7.10.1016/j.ajp.2014.11.006CrossRefGoogle ScholarPubMed
Castaldelli-Maia, JM, da Silva, NR, Campos, MR, Moura, HF, Zabert, G, Champagne, BM, et al. Implementing evidence-based smoking cessation treatment in psychosocial care units (CAPS) in Brazil. Int J Soc Psychiatry 2017; 63: 669–73.10.1177/0020764017731462CrossRefGoogle ScholarPubMed
Zaleski, M, Laranjeira, RR, Marques, A, Ratto, L, Romano, M, Alves, H, et al. Guidelines of the Brazilian Association of Studies on Alcohol and Other Drugs (ABEAD) for diagnoses and treatment of psychiatric comorbidity with alcohol and other drugs dependence. Rev Bras Psiquiatr 2006; 28: 142–8.10.1590/S1516-44462006000200013CrossRefGoogle ScholarPubMed
Asher, L, Hanlon, C, Birhane, R, Habtamu, A, Eaton, J, Weiss, HA, et al. Community-based rehabilitation intervention for people with schizophrenia in Ethiopia (RISE): a 12 month mixed methods pilot study. BMC Psychiatry 2018; 18: 117.10.1186/s12888-018-1818-4CrossRefGoogle Scholar
Hakobyan, S, Vazirian, S, Lee-Cheong, S, Krausz, M, Honer, WG, Schutz, CG. Concurrent disorder management guidelines. Systematic review. J Clin Med 2020; 9: 2406.10.3390/jcm9082406CrossRefGoogle ScholarPubMed
World Health Organization. Mental Health Gap Action Programme (mhGAP) Guideline for Mental, Neurological and Substance use Disorders 3rd ed. WHO, 2023 (https://www.who.int/publications/i/item/9789240084278).Google Scholar
Druss, BG, von Esenwein, SA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry 2006; 28: 145–53.10.1016/j.genhosppsych.2005.10.006CrossRefGoogle ScholarPubMed
Smartt, C, Ketema, K, Frissa, S, Tekola, B, Birhane, R, Eshetu, T, et al. Pathways into and out of homelessness among people with severe mental illness in rural Ethiopia: a qualitative study. BMC Public Health 2021; 21: 113.10.1186/s12889-021-10629-8CrossRefGoogle ScholarPubMed
Mitchell, AJ, Malone, D, Doebbeling, CC. Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies. Br J Psychiatry 2009; 194: 491–9.10.1192/bjp.bp.107.045732CrossRefGoogle ScholarPubMed
Van Boekel, LC, Brouwers, EP, Van Weeghel, J, Garretsen, HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depen 2013; 131: 2335.10.1016/j.drugalcdep.2013.02.018CrossRefGoogle ScholarPubMed
Miller, WR, Rollnick, S. Motivational Interviewing: Helping People Change. Guilford Press, 2012.Google Scholar
Mihretu, A, Nhunzvi, C, Fekadu, A, Norton, S, Teferra, S. Definition and validity of the construct ‘Problematic Khat Use’: a systematic review. Eur Addict Res 2019; 25: 161–72.10.1159/000499970CrossRefGoogle ScholarPubMed
Feyissa, AM, Kelly, JP. A review of the neuropharmacological properties of khat. Progress Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 1147–66.10.1016/j.pnpbp.2007.12.033CrossRefGoogle ScholarPubMed
Ongeri, L, Kirui, F, Muniu, E, Manduku, V, Kirumbi, L, Atwoli, L, et al. Khat use and psychotic symptoms in a rural Khat growing population in Kenya: a household survey. BMC Psychiatry 2019; 19: 110.10.1186/s12888-019-2118-3CrossRefGoogle Scholar
Bhui, K, Warfa, N. Trauma, khat and common psychotic symptoms among Somali immigrants: a quantitative study. J Ethnopharmacol 2010; 132: 549–53.10.1016/j.jep.2010.07.027CrossRefGoogle ScholarPubMed
Babor, T. Alcohol: No Ordinary Commodity: Research and Public Policy. Oxford University Press, 2010.10.1093/acprof:oso/9780199551149.001.0001CrossRefGoogle Scholar
Odenwald, M, Neuner, F, Schawer, M, Elbert, TR, Catani, C, Lingenfelder, B, et al. Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Med 2005; 3: 5.CrossRefGoogle ScholarPubMed
Warfa, N, Bhui, K, Craig, T, Curtis, S, Mohamud, S, Stansfeld, S, et al. Post-migration geographical mobility, mental health and health service utilisation among Somali refugees in the UK: a qualitative study. Health Place 2006; 12: 503–15.10.1016/j.healthplace.2005.08.016CrossRefGoogle ScholarPubMed
Duresso, SW, Matthews, AJ, Ferguson, SG, Bruno, R. Is khat use disorder a valid diagnostic entity? Addiction 2016; 111: 1666–76.10.1111/add.13421CrossRefGoogle ScholarPubMed
Mihretu, A, Fekadu, A, Norton, S, Habtamu, K, Teferra, S. Validation of the problematic khat use screening test: a cross-sectional study. Eur Addict Res 2022; 28: 275–86.10.1159/000522618CrossRefGoogle ScholarPubMed
Andrade, C. The limitations of quasi-experimental studies, and methods for data analysis when a quasi-experimental research design is unavoidable. Indian J Psychol Med 2021; 43: 451–2.10.1177/02537176211034707CrossRefGoogle Scholar
Demissie, M, Hanlon, C, Ng, L, Mayston, R, Fekadu, A. Feasibility and acceptability of a contextualized brief Psychological Intervention for people with bipolar disorder in rural Ethiopia. Pilot Feasibility Stud 2025; 11: 99.10.1186/s40814-025-01683-9CrossRefGoogle Scholar
Figure 0

Fig. 1 PRISMA flow diagram of the study selection process.

Figure 1

Table 1 Characteristics and results of the included studies

Supplementary material: File

Mihretu et al. supplementary material

Mihretu et al. supplementary material
Download Mihretu et al. supplementary material(File)
File 15.2 KB
Submit a response

eLetters

No eLetters have been published for this article.